HC Wainwright reaffirmed their buy rating on shares of DICE Therapeutics (NASDAQ:DICE – Get Rating) in a research report report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $60.00 target price on the stock. HC Wainwright also issued estimates for DICE Therapeutics’ Q1 2023 earnings at ($0.57) EPS, Q3 2023 earnings at ($0.70) EPS and Q4 2023 earnings at ($0.76) EPS.
A number of other equities analysts have also commented on the stock. Cowen began coverage on shares of DICE Therapeutics in a research report on Wednesday, March 1st. They issued an outperform rating for the company. TD Cowen initiated coverage on shares of DICE Therapeutics in a report on Wednesday, March 1st. They issued an outperform rating on the stock. Finally, Cowen initiated coverage on shares of DICE Therapeutics in a report on Wednesday, March 1st. They set an outperform rating on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, DICE Therapeutics currently has a consensus rating of Buy and a consensus price target of $65.86.
DICE Therapeutics Stock Down 2.3 %
Shares of NASDAQ:DICE opened at $28.82 on Thursday. The firm has a market capitalization of $1.37 billion, a PE ratio of -13.47 and a beta of 0.71. DICE Therapeutics has a twelve month low of $12.64 and a twelve month high of $45.99. The company has a 50-day moving average price of $29.87 and a two-hundred day moving average price of $29.43.
Institutional Investors Weigh In On DICE Therapeutics
DICE Therapeutics Company Profile
DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
- Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.